What question did this study set out to answer?

To evaluate the safety and efficacy of combining sasanlimab with stereotactic body radiation therapy for muscle invasive bladder cancer patients ineligible for chemotherapy.

March 4, 2026Journal of Clinical Oncology

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer: The RAD VACCINE MIBC clinical trial.

View Full Paper

Ask AI

Bookmark

Authors

RSRaj Satkunasivam FNFotis Nikolos RTRenil S. Titus

Discussion

Member takes

Overview

Phase II trial demonstrates meaningful pathologic complete response in bladder cancer patients ineligible for chemotherapy, suggesting new treatment potential.

Key Points

To evaluate the safety and efficacy of combining sasanlimab with stereotactic body radiation therapy for muscle invasive bladder cancer patients ineligible for chemotherapy.
Conducted a phase II clinical trial with 33 patients who were ineligible for cisplatin-based chemotherapy.
Administered two doses of sasanlimab with stereotactic body radiation therapy prior to radical cystectomy.
Evaluated the primary endpoint of pathologic complete response (pCR) and secondary endpoints including adverse events and quality of life.
Achieved a 44.8% pathologic complete response rate and 75.9% down-staging to pT0/Ta/T1.
Two-year metastasis-free survival was 72.2%, with 92.3% for pCR patients.
Only 9.1% of patients experienced grade ≥3 treatment-related adverse events, indicating acceptable toxicity.

Cite This Study

Satkunasivam et al. (2026) studied this question.

synapsesocial.com/papers/69a7ccc3d48f933b5eed87c0 https://doi.org/10.1200/jco.2026.44.7_suppl.750

View Full Paper

Ask AI

Bookmark

March 4, 2026Journal of Clinical Oncology

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer: The RAD VACCINE MIBC clinical trial.

View Full Paper

Ask AI

Bookmark

Authors

RSRaj Satkunasivam FNFotis Nikolos RTRenil S. Titus

Discussion

Member takes

Overview

Phase II trial demonstrates meaningful pathologic complete response in bladder cancer patients ineligible for chemotherapy, suggesting new treatment potential.

Key Points

To evaluate the safety and efficacy of combining sasanlimab with stereotactic body radiation therapy for muscle invasive bladder cancer patients ineligible for chemotherapy.
Conducted a phase II clinical trial with 33 patients who were ineligible for cisplatin-based chemotherapy.
Administered two doses of sasanlimab with stereotactic body radiation therapy prior to radical cystectomy.
Evaluated the primary endpoint of pathologic complete response (pCR) and secondary endpoints including adverse events and quality of life.
Achieved a 44.8% pathologic complete response rate and 75.9% down-staging to pT0/Ta/T1.
Two-year metastasis-free survival was 72.2%, with 92.3% for pCR patients.
Only 9.1% of patients experienced grade ≥3 treatment-related adverse events, indicating acceptable toxicity.

Cite This Study

Satkunasivam et al. (2026) studied this question.

synapsesocial.com/papers/69a7ccc3d48f933b5eed87c0 https://doi.org/10.1200/jco.2026.44.7_suppl.750

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark